Peptide Production: HHS Grants Enforcement Discretion to Small Pharmacies

The Department of Health and Human Services announced a new policy that grants enforcement discretion for six peptides, allowing small compounding pharmacies to manufacture them without fear of federal action. This move brings widely used wellness substances out of the gray market and into the regulated pharmacy system.

Health Secretary Robert F. Kennedy Jr., a vocal supporter of the compounds, announced the policy on Tuesday. Peptides are short chains of amino acids that can have powerful effects on the body. While some occur naturally, the six covered by the new rule are synthetic variations. They have been popular among wellness influencers and some clinicians for conditions ranging from migraines to insomnia, despite a lack of rigorous evidence for their safety and effectiveness.

The policy specifically targets 503A compounding pharmacies. These are smaller facilities that produce medications on a case-by-case basis for individual patients. The rule does not apply to 503B outsourcing facilities, which are larger operations that produce bulk quantities of medicines. By focusing on 503A pharmacies, the administration aims to replace illicit "research-use-only" peptides often sourced from overseas suppliers with products made under pharmacy standards.

Joshua Fritzler, president of Olympia and Wesley Pharmaceuticals in central Florida, noted that demand for these compounds has been steady for years. His company had previously avoided making them because they were technically illegal to compound. Under the new guidance, only his smaller 503A facility will be permitted to produce the peptides, and only in limited quantities. Fritzler stated that his firm will likely compound just one of the six peptides and needs to prepare its facility before production can begin.

"We won't be able to meet demand," Fritzler said. He added that he does not believe all 503A pharmacies in the country could satisfy consumer interest. The Alliance for Pharmacy Compounding expressed satisfaction with the decision. CEO Scott Brunner wrote in a statement that the policy offers a more accountable alternative for patients. He noted that the move places patients within a system where pharmacy standards and adverse event reporting apply.

Brunner warned that it may take time for pharmacies to begin dispensing these products. Ingredient suppliers must ensure their active ingredients meet the new policy requirements, and pharmacies must verify this compliance before use. The new policy follows a July vote by an FDA advisory panel that favored expanded access to the six peptides through compounding. However, FDA scientists at that same meeting recommended against unwinding existing restrictions, citing concerns about the evidence.

Consumer advocacy groups have raised objections. Public Citizen, a nonprofit, argued that Kennedy acted unilaterally rather than following the standard rulemaking process. Dr. Robert Steinbrook, the group's health research director, wrote that allowing unproven peptides to be manufactured without concern for federal enforcement undermines the FDA. He advised clinicians to inform patients about risks of contamination and other adverse effects.

The Partnership for Safe Medicines filed a citizen petition last week urging the FDA to ignore the July advisory recommendation. Shabbir Safda, the group's executive director, wrote in a statement that the decision leaves Americans in a gray area regarding safety. He pointed out that the FDA's own scientists had recommended against the change due to evidence concerns. The six peptides covered by the policy are BPC-157, Epitalon, KPV, MOTS-c, Semax, and TB-500.